<DOC>
	<DOCNO>NCT02957864</DOCNO>
	<brief_summary>Tenofovir disoproxil fumarate ( TDF ) one frequently use drug treat HIV . Long term use TDF induce renal toxicity . Tenofovir alafenamide ( TAF ) new pro-drug Tenofovir associate renal toxicity may therefore good substitute TDF patient TDF induce renal toxicity . Abacavir ( ABC ) another drug use treatment HIV associate renal toxicity . In study investigator compare effect renal function switch TDF TAF switch TDF ABC patient TDF induce renal insufficiency .</brief_summary>
	<brief_title>Switching From Tenofovir Disoproxil Fumarate Abacavir Tenofovir Alafenamide</brief_title>
	<detailed_description>The majority HIV-1 infect patient resource rich country receive tenofovir prodrug tenofovir disoproxil fumarate ( TDF ) part combination antiretroviral therapy ( cART ) . Long-term exposure TDF associate accelerate estimate glomerular filtration rate ( eGFR ) decline proximal renal tubular dysfunction ( PTD , see definition ) . The current practice patient TDF relate renal toxicity become apparent substitute abacavir ( ABC ) TDF . However , ABC contraindicate patient HLAB57*01 associate increase risk cardiovascular disease large HIV cohort study , randomize clinical trial . Recently , new tenofovir prodrug , tenofovir alafenamide ( TAF ) develop Gilead Sciences available coformulation emtricitabine ( FTC ) . Due target delivery tenofovir inside CD4 positive cell prodrug , 25 mg TAF need antiviral effect observe patient take 250 mg TDF low TAF dose lead 90 % low serum level tenofovir . In recently complete phase III study patient normal kidney function include , low tenofovir exposure patient TAF show prevent off-target renal bone toxicity comparison patient take TDF . However , whether already establish TDF related renal toxicity HIV patient reverse switch TAF , remain show . Objective : To study renal safety HIV patient TDF relate renal toxicity switch TAF compare current practice switch ABC . Study design : 96 week open label multicenter randomize non-inferiority clinical trial . Study population : HIV-1 infected adult , suppress HIV-RNA &lt; 50c/mL TDF contain antiretroviral regimen , sign TDF relate renal toxicity indicate accelerated eGFR decline . Intervention : Replace TDF TAF ( intervention arm ) ABC ( control arm ) . Main study parameters/endpoints : Primary endpoint : Recovery renal dysfunction TAF arm versus ABC arm 48 week switch TDF TAF ABC use time first eGFR within 75 % eGFR time TDF initiation . Secondary endpoint : See</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>HIVpositive document ELISA Western Blot plasma HIVRNA &gt; 1000 copies/mL . 18 year old . Stable TDF/FTC TDF/3TC ≥12 month ( 365 day ) combination third antiretroviral agent ( NNRTI , INI , PI ) unchanged third agent least 1 month . HIV1 RNA &lt; 50 copies/mL ≥ 6 month . Patient negative HLA B5701 allele . Confirmed/probable TDFrelated accelerate eGFR decline ( one follow ) : 1 . Accelerated eGFR decline : mean &gt; 3 mL/min/year since start TDF ≥5 year TDF exposure . 2 . Confirmed eGFR &lt; 70 mL/min patient baseline eGFR &gt; 90 mL/min start TDF . 3. eGFR decrease &gt; 25 % compare baseline eGFR TDFinitiation . Absence cause eGFR decline : Diabetic patient diabetic nephropathy ( define eGFR decline uACR &gt; 30mg/mmol uAPR &gt; /=0.4 , biopsy proven ) . Hypertensive patient ( define use antihypertensive untreated systolic ( &gt; =160mmHg ) diastolic ( &gt; =95mmHg ) hypertension ) combination hypertensive nephropathy ( define eGFR decline uACR &gt; 30mg/mmol uAPR &gt; /=0.4 , biopsy proven ) . Nephrotic syndromes/nephrotic range proteinuria ( uACR &gt; 300mg/mmol uAPR ≥ 0.4 , total 24hrs proteinuria &gt; 3.5g/24hr , biopsy proven ) Nephrotic syndrome include rapid progressive glomerulonephritis tubular interstitial nephritis ( define active urine sediment erythrocyturia leucocyturia proteinuria eGFR decline , without presence systemic disease , biopsy proven ) . Obvious renal toxic effect related lifestyle medication ( e.g . creatin use ) suspect investigator biopsy proven . Concomittantly use medication interfere trial procedure ( investigator ' discretion ) . Likely cause ( define ) accelerate GFR decline . HLAB5701 positivity . Active hepatitis C B. Documented intermediate high level resistance ABC . eGFR &lt; 30ml/min . Any disease medical condition , opinion investigator , would interfere safety participant conduct trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>